AcouSort publishes Q1 2026 interim report
The company reports net sales TSEK 2,147, loss before tax TSEK -2,369, Werfen prepayment of about USD 1.3 million, and equity ratio improved to 52%.
See the latest news and media coverage for AcouSort. We track all announcements, press releases, and industry mentions in real time, all in one place.
Acoustofluidic sample processing solutions for cells and extracellular vesicles
acousort.comLast updated
In short: AcouSort reported a 36% rise in Q2 2026 net sales, secured a $1.3 million royalty prepayment from Werfen, and expanded its partnerships.
The company reports net sales TSEK 2,147, loss before tax TSEK -2,369, Werfen prepayment of about USD 1.3 million, and equity ratio improved to 52%.
The report is available as a PDF on the company's website and includes financial performance for the fiscal year.
Werfen prepays minimum royalties for 2027-2028, totaling USD 1.3 million with 2026 royalties, funding AcouSort into 2027.
Net sales rise to TSEK 6,853. Losses narrow. New partnerships signed. Equity ratio improves to 91%.
Aug. 26 AcouSort AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI ...
Acousort, a technology company focused on medtech/biotech, reports an operating result for the second quarter of 2026 at minus 3.6 million kronor...
The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037. First quarter 2026 for the Group Net sales amounted to TSEK...
Acousort, a technology company focused on medtech/biotech, reports an operating result for the first quarter of 2026 of -3.0 million kronor (-3.3).
Track AcouSort and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to AcouSort and other trending companies.